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Context: Procalcitonin, a well-known biomarker of sepsis and bacterial infections, is produced by
adipose tissue and has potential as a marker for chronic low-grade inflammation.
Objectives:Theobjectiveof this studywas to investigatewhetherplasmaprocalcitonin levels in the
normal range are associated with obesity, insulin resistance, and metabolic syndrome (MS) in the
general population.
Methods: Plasmaprocalcitonin (0.006–0.1 ng/ml)wasmeasured in 3197men and 3638women (aged
28–75 yr) of the Prevention of Renal and Vascular End-Stage Disease (PREVEND) study using an ultra-
sensitive immunoluminometric assay. MS was defined according to Adult Treatment Panel III criteria.
Results:Median (interquartile range) plasma procalcitonin was 0.018 (0.015–0.022) ng/ml in men
and0.014 (0.012–0.017)ng/ml inwomen (P0.001). Plasmaprocalcitoninwaspositivelyassociated
withbodymass index andwaist circumference. In both sexes, cross-sectional associations of plasma
procalcitonin with insulin resistance and components of theMS remained significant after adjust-
ment for age, body mass index, waist circumference, and other covariates. The age-adjusted odds
ratio (OR) forMSwas 3.2 [95%confidence interval (CI)2.5–4.2) inmenand4.1 (95%CI3.0–5.5)
in women, when comparing the highest with the lowest quartile of plasma procalcitonin. The
multivariate-adjusted OR for MS was 1.9 (95% CI 1.4–2.6) in men and 2.3 (95% CI 1.6–3.3) in
women. Themultivariate-adjustedOR for insulin resistancewas 3.3 (95%CI 2.4–4.3) inmen and
2.5 (95% CI  1.9–3.4) in women.
Conclusions: Elevated plasma procalcitonin levels in the normal range are associated with mea-
sures of obesity, insulin resistance, andMS in the general population. (J Clin Endocrinol Metab 95:
E26–E31, 2010)
There are strong links between obesity, insulin resis-tance, and components of the metabolic syndrome.
Chronic low-grade inflammation has been implicated in the
pathophysiology of these three intertwined entities (1, 2).
Procalcitonin, a 116-amino-acid polypeptide, is the
precursor of calcitonin hormone produced by neuroendo-
crineC-cells of the thyroid andK-cells of the lung, encoded
from the calcitonin I (CALCI) gene on chromosome 11
(3–5). Procalcitonin is best known as a biomarker of in-
fection and severe systemic inflammation (6, 7). Recent
studies show that adipose tissue is capable of expressing
and secreting procalcitonin (8–10). This makes procalci-
tonin a potential biomarker for obesity-related low-grade
inflammation.
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Abbreviations: BMI, Body mass index; CI, confidence interval; HDL, high-density lipopro-
tein; HOMA-IR, homeostasis model assessment for insulin resistance; hs-CRP, high-sensi-
tivity C-reactive protein; IQR, interquartile range.
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There are no data addressing the significance of varia-
tion in plasma procalcitonin levels in the general popula-
tion. So far, procalcitonin level in the normal population
has been studied only in a small sample, and only an as-
sociation of procalcitonin with sex was acknowledged
(11). We hypothesize that plasma procalcitonin may be
associated with measures of obesity, insulin resistance,
and metabolic risk factors.
Subjects and Methods
This cross-sectional analysis was conducted on the participants
from the Prevention of Renal and Vascular End-Stage Disease
(PREVEND) study in the general population (age ranged from
28–75 yr) of the city of Groningen, The Netherlands. Details of
the study design, recruitment, and procedures have been pub-
lished elsewhere (12). Plasma procalcitonin was measured in
7690 participants from the samples of the baseline screening. At
first, we excluded 25 participantswith procalcitonin level higher
than 0.1 ng/ml. Further exclusion was for 385 individuals who
had no documented fasting blood samples or missing data for
other variables, leaving 3137 men and 3638 women (total, n
6835) for the present analysis. The PREVEND study was ap-
provedby the localmedical ethics committee,UniversityMedical
Center Groningen, and conformed to the principles outlined in
the Declaration of Helsinki. All participants gave written in-
formed consent.
Blood pressure was measured in supine position with an au-
tomatic device (Dinamap XL model 9300; Johnson-Johnson
Medical, Tampa, FL). Smoking and alcohol use were based on
self-reports. Metabolic syndrome was defined according to the
National Cholesterol Education Program’s Adult Treatment
Panel III report criteria (13), as participants having at least three
of the following: 1) waist circumference more than 35 in. (88
cm) in women or more than 40 in. (102 cm) in men, 2) blood
pressure at least 130/85 mm Hg or treatment for hypertension,
3) fasting triglycerides at least 150 mg/dl (1.7 mmol/liter), 4)
high-density lipoprotein (HDL) cholesterol no higher than 40
mg/dl (1.0mmol/liter) inmenornohigher than50mg/dl (1.3
mmol/liter) in women, and 5) fasting blood glucose at least 110
mg/dl (6.1mmol/liter) or treatment for type 2 diabetes. Insulin
resistance was assessed based on the homeostasis model assess-
ment for insulin resistance (HOMA-IR) that is calculated using
the following formula: [glucose (millimoles per liter)  insulin
(milliunits per milliliter)]/22.5 (14). We defined insulin resis-
tance as a HOMA-IR score in upper sex-specific quartiles.
In baseline samples, serum and urinary creatinine, total cho-
lesterol, and plasma glucose were measured by dry chemistry
(Eastman Kodak, Rochester, NY). HDL cholesterol was mea-
suredwith ahomogeneousmethod (directHDL,Aeroset System;
Abbott Laboratories, Abbott Park, IL). Triglycerides were mea-
sured enzymatically. High-sensitivity C-reactive protein (hs-
CRP) was determined by nephelometry (BN II; Dade Behring,
Marburg, Germany). Urinary albumin excretion was measured
as the mean of two 24-h urine collections by nephelometry with
a threshold of 2.3 mg/liter (Dade Behring Diagnostic, Marburg,
Germany). Insulin was measured with an AxSym autoanalyzer
(Abbott Diagnostics, Amstelveen, The Netherlands). Procalci-
tonin was measured by a novel commercially available immu-
noluminometric assay (BRAHMS PCT sensitive LIA; Hennigs-
dorf, Germany). Assays were performed in EDTA-plasma
aliquots that had been stored frozen at80 C, without previous
thawing and refreezing. The intraassayCV at 0.1 ng/mlwas 6%,
and at 0.03 ng/ml it was 8%. The functional assay sensitivity,
defined as the lowest concentration to be determined with an
interassay CV of 20% was 0.007 ng/ml. The lowest detection
limit was 0.006 ng/ml. The assay technique has been described
previously (11). All technicians were blinded to the participants’
characteristics.
Continuous variables were compared by using one-way
ANOVA or a Kruskal-Wallis test, and a 2 test was used for the
categorical variables to test for differences across quartiles of
procalcitonin. We evaluated the association of log2 procalcito-
nin level with the components (continuous) of the metabolic
syndrome using univariate and multivariate-adjusted linear re-
gression models in sex-stratified analyses. Regression coeffi-
cients with 95% confidence intervals (CI) were determined. We
performed univariate and multivariate-adjusted logistic regres-
sionmodels to test the association between plasmaprocalcitonin
level and presence of the metabolic syndrome and insulin resis-
tance. The models were adjusted for age, measures of obesity,
hs-CRP, tobacco smoking, alcohol use, history of cardiovascular
disease, and hormone replacement therapy (for women). A P
value 0.05 from two-sided tests was considered statistically
significant. The statistical analyses were performed using SPSS
version 16.0 statistical software (SPSS Inc., Chicago, IL).
Results
Of 3197 men and 3638 women, 631 (19.7%) and 616
(16.9%) hadmetabolic syndrome, respectively.Median [in-
terquartile range (IQR)] procalcitonin levels were 0.018
(0.015–0.022)ng/ml inmenand0.014(0.012–0.017)ng/ml
in women (P  0.001). Anthropometric and clinical char-
acteristics of the study population are summarized in Table
1 formenandwomenseparately. Participantswithhighpro-
calcitonin levels were older, more obese, and more likely to
fulfill criteria for the metabolic syndrome. They also had
lower insulin sensitivity, lower creatinine clearance, higher
hs-CRP, and higher urinary albumin excretion. Men with
high procalcitonin were more likely to be smoker or ex-
smoker, whereas women with high procalcitonin were less
likely to use alcohol.
In men, across quartiles of body mass index (BMI) me-
dian (IQR) procalcitonin levels gradually increased from
0.016 (0.014–0.020) ng/ml in the first to 0.020 (0.016–
0.024) ng/ml in the fourth quartile (P  0.001) (Supple-
mental Fig. 1, published on The Endocrine Society’s Jour-
nals Online web site at http://jcem.endojournals.org). In
women, this was from 0.013 (0.011–0.015) ng/ml in the
first to 0.016 (0.014–0.019) ng/ml in the fourth quartile
(P  0.001). In men, across quartiles of waist circumfer-
ence, median (IQR) procalcitonin increased from 0.016
(0.014–0.020) ng/ml in the first to 0.019 (0.016–0.022)
ng/ml in the fourth quartile (P  0.001). In women, this
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TABLE 1. Anthropometric and clinical characteristics of participants according to sex-specific quartiles of plasma
procalcitonin (n  6835)
Characteristic
Procalcitonin quartiles (ng/ml)
P value1 2 3 4
Male 0.008–0.015 0.016–0.018 0.019–0.022 0.023–0.098
Female 0.006–0.012 0.013–0.014 0.015–0.017 0.018–0.098
No. of participants
Male 887 806 769 735
Female 1043 906 868 821
Age (yr)
Male 46.0  12.0 48.9  12.5 51.1  12.9 52.8  12.9 0.001
Female 42.5  9.7 45.6  10.8 49.6  12.3 55.2  12.3 0.001
History of cardiovascular disease n (%)
Male 60 (6.8) 58 (7.2) 75 (9.8) 81 (11.0) 0.005
Female 16 (1.5) 20 (2.2) 35 (4.0) 38 (4.6) 0.001
BMI (kg/m2)
Male 25.0  3.3 26.0  3.3 26.8  3.6 27.3  3.8 0.001
Female 24.4  3.8 25.2  4.2 26.3  4.8 27.8  5.2 0.001
Weight n (%)
Male
Normal 465 (52.4) 314 (39.0) 247 (32.1) 198 (26.9) 0.001
Overweight 365 (41.1) 402 (49.9) 390 (50.7) 374 (50.9)
Obese 57 (6.4) 90 (11.2) 132 (17.2) 163 (22.2)
Female
Normal 668 (64.0) 498 (55.0) 391 (45.0) 259 (31.5) 0.001
Overweight 293 (28.1) 294 (32.5) 316 (36.4) 319 (38.9)
Obese 82 (7.9) 114 (12.6) 161 (18.5) 243 (29.6)
Waist circumference (cm)
Male 89.6  10.2 93.0  10.1 95.6  10.7 97.1  11.5 0.001
Female 80.0  10.8 84.8  11.9 90.2  12.2 94.6  12.3 0.001
Systolic blood pressure (mm Hg)
Male 124.9  16.1 126.9  16.6 129.9  18.1 132.5  18.6 0.001
Female 113.6  15.9 116.9  17.8 121.0  20.1 127.9  21.4 0.001
Diastolic blood pressure (mm Hg)
Male 72.3  9.1 73.5  8.9 75.3  9.3 76.8  9.9 0.001
Female 66.7  8.4 68.1  8.7 69.4  9.1 71.4  8.5 0.001
Total cholestrol (mmol/liter)
Male 5.4  1.0 5.6  1.1 5.8  1.0 5.8  1.1 0.001
Female 5.3  1.0 5.5  1.1 5.7  1.2 6.0  1.2 0.001
HDL cholesterol (mmol/liter)
Male 1.2  0.3 1.1  0.3 1.1  0.3 1.1  0.3 0.001
Female 1.6  0.4 1.5  0.4 1.5  0.4 1.4  0.4 0.001
Triglyceride (mmol/liter)
Male 1.3  0.8 1.5  0.9 1.7  1.1 1.8  1.5 0.001
Female 1.0  0.4 1.1  0.7 1.3  0.7 1.6  1.0 0.001
Glucose (mmol/liter)
Male 4.8  0.8 4.9  1.0 5.0  1.0 5.3  1.6 0.001
Female 4.5  0.7 4.6  0.7 4.7  0.9 5.2  1.6 0.001
Insulin (mU/liter)
Male 6.8 (4.9–9.7) 7.9 (5.6–11.9) 9.2 (6.2–13.2) 10.5 (6.9–15.6) 0.001
Female 6.5 (4.8–8.7) 7.1 (5.2–10.1) 7.8 (5.5–11.2) 9.9 (6.5–15.4) 0.001
HOMA-IR
Male 1.4 (1.0–2.1) 1.7 (1.2–2.6) 2.0 (1.3–3.1) 2.4 (1.5–3.7) 0.001
Female 1.3 (0.9–1.8) 1.4 (1.0–2.1) 1.6 (1.1–2.5) 2.2 (1.3–3.6) 0.001
Tobacco smoking n (%)
Male
Never 266 (30.0) 216 (26.8) 175 (22.8) 167 (22.7)
Quit 318 (35.9) 301 (37.3) 310 (40.3) 348 (47.3) 0.001
Current smoker 303 (34.2) 289 (35.9) 284 (36.9) 220 (29.9)
Female
Never 356 (34.1) 294 (32.5) 313 (36.1) 279 (34.0)
Quit 344 (33.0) 285 (31.5) 285 (32.8) 271 (33.0) 0.861
Current smoker 343 (32.9) 327 (36.1) 270 (31.1) 271 (33.0)
(Continued)
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was from 0.013 (0.011–0.015) ng/ml in the first to 0.016
(0.014–0.020) ng/ml in the fourth quartile (P  0.001).
Associations of components of the metabolic syndrome
(waist circumference, systolic blood pressure, diastolic
blood pressure, triglycerides, HDL cholesterol, glucose)
and insulin resistance (fasting insulin and HOMA-IR)
with procalcitonin were independent of age in linear re-
gression analyses. Further adjustment for BMI attenuated
these associations, but they remained statistically signifi-
cant. Subsequent further adjustments for hs-CRP, smok-
ing status, alcohol intake, history of cardiovascular dis-
ease, and hormone replacement therapy (for women) did
not materially change these associations except for blood
pressure, which lost significance in women (Supplemental
Table 1).
Logistic regression analyses (Table 2) show that risk for
the metabolic syndrome and insulin resistance increased
across procalcitonin quartiles. In multivariate-adjusted
models, the odds ratios for metabolic syndrome and in-
sulin resistance in the highest quartile compared with the
lowest were 1.9 (95% CI 1.4–2.6) and 3.3 (95% CI
2.4–4.3) in men and 2.3 (95% CI  1.6–3.3) and 2.5
(95% CI  1.9–3.4) in women, respectively.
Discussion
To the best of our knowledge, this study explored for the
first time the association of plasma procalcitonin with
measures of obesity andmetabolic and cardiovascular risk
factors in a large sample of the general population. An
important finding is that variation inplasmaprocalcitonin
within the normal range is associated with insulin resis-
tance and the metabolic syndrome in apparently healthy
men andwomen. The association of plasma procalcitonin
with insulin resistance and metabolic syndrome was in-
dependent of age, measures of obesity, hs-CRP, history of
cardiovascular disease, and health behaviors.
The current results are in line with experimental and
observational data that suggest that plasma procalcitonin
can be an inflammatory biomarker even in the absence of
signs of systemic infection or sepsis (8–10, 15, 16). Hu-
man adipose tissue depots have been identified as major
nonneuroendocrine calcitonin mRNA expression sites (8,
9), and in vitro secretion of procalcitonin by adipocytes
was stimulated by activated macrophages (9). Because
obesity is associated with increased macrophage infiltra-
tion into adipose tissue, a similar scenario may play a role
in vivo. In a recent publication, an association of plasma
procalcitoninwith central body fat distributionwas found
in women with polycystic ovary syndrome (15). In line
with this, we found a significant independent association
of waist circumference with procalcitonin in both sexes.
The associations of plasma procalcitonin levels with
insulin resistance and components of the metabolic syn-
drome were attenuated after adjustment for BMI and




P value1 2 3 4
Alcohol use n (%)
Male
Never 125 (14.1) 143 (17.7) 143 (18.6) 136 (18.5)
1–4 drinks/month 90 (10.1) 94 (11.7) 88 (11.4) 97 (13.2)
2–7 drinks/wk 370 (41.7) 307 (38.1) 263 (34.2) 253 (34.4) 0.118
1–3 drinks/d 223 (25.1) 201 (24.9) 211 (27.4) 181 (24.6)
4 drinks/d 79 (8.9) 61 (7.6) 64 (8.3) 68 (9.3)
Female
Never 280 (26.8) 265 (29.2) 308 (35.5) 313 (38.1)
1–4 drinks/month 200 (19.2) 183 (20.2) 155 (17.9) 167 (20.3)
2–7 drinks/wk 375 (36.0) 305 (33.7) 245 (28.2) 216 (26.3) 0.001
1–3 drinks/d 173 (16.6) 130 (14.3) 147 (16.9) 105 (12.8)
4 drinks/d 15 (1.4) 23 (2.5) 13 (1.5) 20 (2.4)
Creatinine clearance (ml/min)
Male 117.4  26.5 114.3  25.8 113.8  28.1 111.5  27.4 0.001
Female 98.1  21.4 99.1  21.3 96.1  25.1 91.4  24.5 0.001
Urine albumin excretion (mg/24 h)
Male 9.1 (6.6–16.7) 9.9 (6.8–17.3) 10.7 (7.1–20.9) 13.0 (7.5–31.9) 0.001
Female 7.8 (5.7–12.1) 8.1 (5.7–13.2) 8.5 (6.0–14.0) 10.0 (6.4–18.6) 0.001
hs-CRP (mg/liter) (n  6617)
Male 0.7 (0.3–1.7) 1.0 (0.5–2.4) 1.3 (0.7–2.7) 2.0 (1.0–4.4) 0.001
Female 0.9 (0.4–2.2) 1.1 (0.5–2.5) 1.4 (0.6–3.3) 2.3 (1.0–5.1) 0.001
P values are based on 2 test for categorical data, Spearman rank correlation for ordinal data, and ANOVA or Kruskal-Wallis for continuous data,
depending on the normality of the data, which are presented as mean  SD or median (IQR).
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view that circulating levels of procalcitonin are partly de-
pendent on adipose tissuemass. However, another part of
the associations was independent of BMI. Possible expla-
nations are that circulating levels of procalcitonin are
related to adipocyte function rather than mass or that
other factors that link inflammation to the metabolic
syndrome play a role, e.g. nonassessed atherosclerosis
(17) or periodontitis (18).
This study extends the available information for pro-
calcitonin to a role as a biomarker of noninfectious con-
ditions, namely the metabolic and cardiovascular arena.
Moreover, because plasmaprocalcitonin can nowbemea-
sured within the normal range, it warrants further re-
search into its potential to identify individuals at risk of
cardiovascular and chronic metabolic disease.
There are several limitations of this study. The study is
a cross-sectional investigation, and causal relationships of
procalcitonin as a novel biomarker of the metabolic syn-
drome and insulin resistance cannot be inferred. Another
limitation is the use of insulin resistance based on
HOMA-IR instead of the gold standard hyperinsuline-
mic-euglycemic clamp technique. Although our study
included apparently healthy adults, mostly recruited
from Caucasians in The Netherlands, it is unclear
whether our findings would be replicable in other re-
gions and among unhealthy individuals with cardiovas-
cular or other comorbidities.
In conclusion, our findings based on community-based
data show that higher plasma procalcitonin levels in the
normal range are associated with increased measures of
obesity, components of the metabolic syndrome, and
greater risk of having metabolic syndrome and insulin re-
sistance. Because associations only partly depend on BMI,
plasma procalcitonin may serve as a new marker for adi-
pocyte dysfunction, chronic low-grade inflammation, or
both.
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TABLE 2. Odds ratios (OR) for metabolic syndrome and insulin resistance according to sex-specific quartiles of
plasma procalcitonin
Procalcitonin quartiles (ng/ml)
P value for trend1 2 3 4
Men
No. of persons 887 806 769 735
Metabolic syndrome
No. of cases 94 137 169 231
Unadjusted OR (95% CI) 1.00 1.7 (1.3–2.3) 2.4 (1.8–3.1) 3.9 (3.0–5.0) 0.001
Age-adjusted OR (95% CI) 1.00 1.6 (1.2–2.1) 2.1 (1.6–2.7) 3.2 (2.5–4.2) 0.001
Multivariate OR (95% CI)b 1.00 1.2 (0.9–1.7) 1.3 (0.9–1.8) 1.9 (1.4–2.6) 0.001
Insulin resistancea
No. of cases 103 168 223 303
Unadjusted OR (95% CI) 1.00 2.0 (1.5–2.6) 3.1 (2.4–4.0) 5.3 (4.1–6.9) 0.001
Age-adjusted OR (95% CI) 1.00 1.9 (1.4–2.5) 2.8 (2.2–3.6) 4.7 (3.6–6.0) 0.001
Multivariate OR (95% CI)b 1.00 1.6 (1.2–2.1) 2.1 (1.6–2.8) 3.3 (2.4–4.3) 0.001
Women
No. of person 1043 906 868 821
Metabolic syndrome
No. of cases 66 102 160 288
Unadjusted OR (95% CI) 1.00 1.9 (1.4–2.6) 3.3 (2.5–4.5) 8.0 (6.0–10.7) 0.001
Age-adjusted OR (95% CI) 1.00 1.5 (1.1–2.2) 2.2 (1.6–3.0) 4.1 (3.0–5.5) 0.001
Multivariate OR (95% CI)b 1.00 1.3 (0.9–1.8) 1.3 (0.9–1.9) 2.3 (1.6–3.4) 0.001
Insulin resistancea
No of cases 132 168 242 367
Unadjusted OR (95% CI) 1.00 1.6 (1.2–2.0) 2.7 (2.1–3.4) 5.6 (4.4–7.0) 0.001
Age-adjusted OR (95% CI) 1.00 1.4 (1.1–1.8) 2.1 (1.7–2.7) 3.9 (3.0–4.9) 0.001
Multivariate OR (95% CI)b 1.00 1.2 (0.9–1.7) 1.4 (1.2–1.9) 2.5 (1.9–3.4) 0.001
a Insulin resistance defined as cases with homeostasis model assessment score in upper quartile, namely above 2.8 and 2.3 for men and women,
respectively.
b Odds ratios (OR) with corresponding 95% CI has been adjusted for age, BMI, hs-CRP, tobacco smoking, alcohol use, history of cardiovascular
diseases, and hormone replacement therapy (for women) in 6617 participants with hs-CRP available.
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